CDSCO Panel Approves Bristol Myers Squibb’s Protocol Amendment Proposal to study Anti-cancer Drug Iberdomide

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the Bristol Myers Squibb’s proposal for protocol amendment to study Iberdomide.

This came firm presented protocol amendment 2.0 dated 29 Oct 2024 protocol no. IM048022 .

Iberdomide is a novel oral cereblon E3 ligase modulator being investigated for the treatment of multiple myeloma and other cancers, showing promising efficacy and safety as a monotherapy or in combination with other therapies.

Iberdomide is a type of drug that modulates the cereblon E3 ligase complex, a protein complex involved in protein degradation.

It induces the ubiquitination and degradation of the hematopoietic transcription factors Aiolos and Ikaros, which are involved in the regulation of immune cells and cancer cell growth.

At the recent SEC meeting for Oncology held on 11th March 2025, the expert panel reviewed the protocol amendment 2.0 dated 29 Oct 2024 protocol no. IM048022.

After detailed deliberation, the committee recommended the approval of the protocol amendment as presented by the firm.

Also Read:Synokem Pharmaceutical Gets CDSCO Panel Nod To Study Anti-rheumatoid drug Iguratimod